search
Back to results

Balloon Cryoablation Without Contrast (CRY-OUT-CAT)

Primary Purpose

Paroxysmal Atrial Fibrillation

Status
Unknown status
Phase
Not Applicable
Locations
Poland
Study Type
Interventional
Intervention
Cryoballoon ablation without contrast
Sponsored by
Medicover Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Paroxysmal Atrial Fibrillation

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with paroxysmal AF - episodes lasting up to 7 days or cardioverted before this time
  • At least 4 AF attacks in the last 12 months
  • Informed consent for participation in the study
  • Age > 18 and < 70 years
  • Left atrium diameter (PLAX) < 4,5 cm and left atrial area < = 30 cm2
  • Left ventricle ejection fraction > 45%
  • Four separate veins visualised in computed tomography prior to the ablation

Exclusion Criteria:

  • Withdrawal of consent for the procedure
  • Documented typical atrial flutter prior to the ablation
  • Thrombus in left atrium
  • GFR < 60 ml/min
  • Pregnancy
  • Common trunk of left or right pulmonary veins documented on computed tomography (preferred) or by means of other imaging methods
  • Other conditions that preclude AF ablation including: infection, uncontrolled hyperthyroidism, significant anaemia and thrombocytopenia, acute cardiac / internist / surgical conditions

Sites / Locations

  • Medicover HospitalRecruiting
  • National Institute of CardiologyRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Cryoballoon ablation without contrast

Arm Description

Cryoballoon ablation without contrast

Outcomes

Primary Outcome Measures

Isolation of a pulmonary vein without the use of contrast and within the scheduled timeframe
Acute result will be assessed. Vein isolation assessment will be done using a diagnostic circular catheter (Achieve, Medtronic), by demonstrating entrance and exit block

Secondary Outcome Measures

Percentage of patients in whom isolation of all pulmonary veins will be achieved without the use of contrast
Percentage of patients with stable sinus rhythm, without atrial fibrillation episodes during follow-up
The amount of contrast dye used
X-ray time exposure
Radiation dose
Left atrial dwelling time
Number of complications assessed

Full Information

First Posted
April 5, 2020
Last Updated
September 4, 2020
Sponsor
Medicover Hospital
Collaborators
National Institute of Cardiology, Warsaw, Poland
search

1. Study Identification

Unique Protocol Identification Number
NCT04344743
Brief Title
Balloon Cryoablation Without Contrast
Acronym
CRY-OUT-CAT
Official Title
Cryoballoon Ablation Without Use of Contrast Dye for the Treatment of Paroxysmal Atrial Fibrillation
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Unknown status
Study Start Date
August 13, 2020 (Actual)
Primary Completion Date
August 2021 (Anticipated)
Study Completion Date
June 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Medicover Hospital
Collaborators
National Institute of Cardiology, Warsaw, Poland

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes

5. Study Description

Brief Summary
Pulmonary vein isolation using cryoballoon ablation is well established method for the treatment of atrial fibrillation. As a rule, cryoenergy delivery is preceded by documenting the full vein occlusion. It is assessed by venography, performed by injecting contrast through the inner lumen of the balloon catheter after the vein is blocked with a balloon. Achieving full vein occlusion in certain situations can be challenging and may require multiple attempts, which may expose the patient to increased doses of contrast and radiation.. At the same time, the purpose of ablation is an electrical isolation of pulmonary veins. Experts postulate ablation in the antrum and the so-called "proximal-seal technique", which in some cases may require to start cryoapplication before the vein is fully sealed. This approach minimizes the risk of the pulmonary vein stenosis, damage to structures immediately adjacent to the atrium and phrenic nerve palsy. In addition, in many cases the displacement of the balloon after several dozen seconds of cryoapplication, usually by pulling it, causes full sealing of the vein, contributes to further lowering the temperature and leads to full electrical isolation of the vein, which is the aims of ablation. All the above-mentioned facts indicate that demonstrating full vein occlusion using angiography before the initiation of cryoenergy application is of limited value. Moreover, there are a number of parameters related to cryoballoon ablation that indicate acute and long term vein isolation. Taking into account the arguments presented above, it seems that it is possible to perform an effective and safe isolation of the pulmonary veins using the cryoballoon ablation technique without confirmation by venography that PV is occluded. Along with dissemination of the method, such attempts are and will be made by some operators. Therefore, a systematic approach to this issue is important. It should define the conditions that should be met in order for the procedure in the proposed modification to be implemented effectively and safely. In addition, a protocol of ablation for this modification is required.
Detailed Description
Pulmonary vein isolation using cryoballoon ablation is well established method for the treatment of atrial fibrillation. As a rule, cryoenergy delivery is preceded by documenting the full vein occlusion. It is assessed by venography, performed by injecting contrast through the inner lumen of the balloon catheter after the vein is blocked with a balloon. Achieving full vein occlusion in certain situations can be challenging and may require multiple attempts, which may expose the patient to increased doses of contrast and radiation.. At the same time, the purpose of ablation is an electrical isolation of pulmonary veins. Experts postulate ablation in the antrum and the so-called "proximal-seal technique", which in some cases may require to start cryoapplication before the vein is fully sealed. This approach minimizes the risk of the pulmonary vein stenosis, damage to structures immediately adjacent to the atrium and phrenic nerve palsy. In addition, in many cases the displacement of the balloon after several dozen seconds of cryoapplication, usually by pulling it, causes full sealing of the vein, contributes to further lowering the temperature and leads to full electrical isolation of the vein, which is the aims of ablation. All the above-mentioned facts indicate that demonstrating full vein occlusion using angiography before the initiation of cryoenergy application is of limited value. Moreover, there are a number of parameters related to cryoballoon ablation that indicate acute and long term vein isolation. Taking into account the arguments presented above, it seems that it is possible to perform an effective and safe isolation of the pulmonary veins using the cryoballoon ablation technique without confirmation by venography that PV is occluded. Along with dissemination of the method, such attempts are and will be made by some operators. Therefore, a systematic approach to this issue is important. It should define the conditions that should be met in order for the procedure in the proposed modification to be implemented effectively and safely. In addition, a protocol of ablation for this modification is required. Course of ablation. All ablations will be performed using Medtronic Arctic Front Advance catheter system as well as future generations of Medtronic cryoballoon catheter systems. Initially the cryoenergy will be delivered without previous venography confirming full vein occlusion. Then, in case of vein isolation failure after 5 minutes of cryoenergy delivery, further attempts to isolate the vein will be preceded by venography. Statistical analysis. The assumed sample size (N = 50 patients/ 200 veins) will allow to estimate the number and percentage of pulmonary veins that will be isolated without the use of contrast. The statistical analysis will use standard descriptive statistics tools: frequency tables for categorical variables; extreme values, mean value and standard deviation for normal distributed variables; and extreme values and quartiles for non-normal distributed variables. Parameters assessed during the procedure: Concerning a single energy cryoapplication Possibility of registration (occurrence vs. non-occurrence) of pulmonary vein potentials before the cryoapplication, and after the occlusion of the vein by the balloon. Time to vein isolation Cryoenergy application time / freezing time The minimum temperature obtained during cryoapplication Time to obtain temperature - 30 ° C and - 40 ° C Temperature after 30, 60 and 90 seconds from the beginning of cryoenergy application Cryoballoon heating time from -30 C to +15 C Concerning the isolation of a single vein Total time to complete isolation of a vein The number of cryoenergy applications Total time of cryoenergy application per vein Concerning the entire procedure: Total cryoenergy application time per procedure / patient The total amount of contrast Radiation dose Time of radiation Left atrial dwelling time Duration of the procedure (from puncture of the vein to sheaths removal) Termination of cryoenergy delivery: If temperature does not reach - 30 ° C after 60 seconds of cryoenergy application (inefficient application). If vein isolation does not occur after 90 seconds of cryoenergy application (inefficient application). If temperature after 30 seconds of cryoapplication falls lower than - 50° C (unsafe application). When temperature reaches - 55° C (unsafe application). If phrenic nerve injury occurs or if symptoms suggesting its imminent occurrence are noticed (unsafe application). If the operator considers that the application is ineffective or performed too distally (inefficient or unsafe application). Effective cryoenergy applications will be terminated 120 seconds after vein isolation. Veins with no recordable pulmonary vein potentials - The above-mentioned veins will be isolated - 1 application 240 seconds. Applications will be considered effective if the minimum temperature achieved will be less than 35C and the stimulation performed from the vein after application will be ineffective. Supplemental cryoapplications. Supplemental cryoenergy applications will not be delivered after successful isolation of the vein Vein isolation assessment. Pulmonary vein isolation will be assessed by demonstrating entrance and exit block Phrenic nerve function monitoring. In order to prevent PN injury/ palsy the balloon will be inflated outside PV ostia and maintained as antrally as possible during vein isolation. For phrenic nerve function monitoring pacing of the nerve during right pulmonary vein isolation will be performed. Additionally, intermittent fluoroscopy during pacing will be used for monitoring diaphragmatic motion. The ablation will be stopped at the first sign of imminent phrenic nerve injury. Complications assessed. Transient phrenic nerve injury or palsy (resolving until discharge after index procedure) is considered a minor complication. Death, stroke, tamponade, arteriovenous fistula or pseudoaneurysm, persistent (resolving during follow up) or permanent (if not resolved at end of follow up, but >12 months) phrenic nerve palsy, bleeding with a decrease in haemoglobin of at least 2 g / dl or any other state requiring prolongation of hospitalization are considered major complications. The duration of the project and follow-up. The study is expected to last two years. Approximately 50 patients will be enrolled, with one year follow-up. All patients will have follow-up visits in an out-patient clinic at least 3 and 12 months post PVI. Additionally at 6 weeks, 6 and 9 months post ablation telephone follow-up will be conducted by the study coordinator using standardized questionnaire.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Paroxysmal Atrial Fibrillation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cryoballoon ablation without contrast
Arm Type
Experimental
Arm Description
Cryoballoon ablation without contrast
Intervention Type
Device
Intervention Name(s)
Cryoballoon ablation without contrast
Intervention Description
Cryoballoon ablation without contrast
Primary Outcome Measure Information:
Title
Isolation of a pulmonary vein without the use of contrast and within the scheduled timeframe
Description
Acute result will be assessed. Vein isolation assessment will be done using a diagnostic circular catheter (Achieve, Medtronic), by demonstrating entrance and exit block
Time Frame
Through study completion, an average of 2 years
Secondary Outcome Measure Information:
Title
Percentage of patients in whom isolation of all pulmonary veins will be achieved without the use of contrast
Time Frame
Through study completion, an average of 2 years
Title
Percentage of patients with stable sinus rhythm, without atrial fibrillation episodes during follow-up
Time Frame
During one year follow-up
Title
The amount of contrast dye used
Time Frame
Through study completion, an average of 2 years
Title
X-ray time exposure
Time Frame
Through study completion, an average of 2 years
Title
Radiation dose
Time Frame
Through study completion, an average of 2 years
Title
Left atrial dwelling time
Time Frame
Through study completion, an average of 2 years
Title
Number of complications assessed
Time Frame
Through study completion, an average of 2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with paroxysmal AF - episodes lasting up to 7 days or cardioverted before this time At least 4 AF attacks in the last 12 months Informed consent for participation in the study Age > 18 and < 70 years Left atrium diameter (PLAX) < 4,5 cm and left atrial area < = 30 cm2 Left ventricle ejection fraction > 45% Four separate veins visualised in computed tomography prior to the ablation Exclusion Criteria: Withdrawal of consent for the procedure Documented typical atrial flutter prior to the ablation Thrombus in left atrium GFR < 60 ml/min Pregnancy Common trunk of left or right pulmonary veins documented on computed tomography (preferred) or by means of other imaging methods Other conditions that preclude AF ablation including: infection, uncontrolled hyperthyroidism, significant anaemia and thrombocytopenia, acute cardiac / internist / surgical conditions
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Pawel Derejko, MD, PhD
Phone
+48603338871
Email
pawel.derejko@medicover.pl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pawel Derejko, MD, PhD
Organizational Affiliation
Medicover Hospital, Warsaw, Poland
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medicover Hospital
City
Warsaw
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pawel Derejko, MD, PhD
Phone
+48603338871
Email
pderejko@yahoo.com
First Name & Middle Initial & Last Name & Degree
Marta Sobczynska, MD
Phone
+48666308590
Email
marta.sobczynska@medicover.pl
Facility Name
National Institute of Cardiology
City
Warsaw
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michal Orczykowski, MD, PhD
Phone
+48696775533
Email
mikeorczyk@gmail.com

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Individual participant data that underlie the results reported in this article, after deidentification (text, tables,figures, and appendices).
IPD Sharing Time Frame
Beginning 3 months and ending 5 years following article publication.
IPD Sharing Access Criteria
Investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for this purpose. For individual participant data meta-analysis

Learn more about this trial

Balloon Cryoablation Without Contrast

We'll reach out to this number within 24 hrs